A Jefferies analyst who lowered his rating on Johnson & Johnson's stock says shares are now fairly valued after climbing since the conglomerate closed its purchase of orthopedic product maker Synthes in June. Analyst Jeffrey Holford downgraded shares of J&J to "Hold" from "Buy."
Breast cancer cells puncture holes into neighboring tissues and crawl though the spaces they create to spread around the body. Scientists at Cancer Research UK’s Beaton Institute in Glasgow discovered that there are high levels of a protein called N-WASP in breast cancer cells.
The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer. Triple-negative breast cancers do not express the three common targets of breast cancer treatments.
Cancer drug developer Myrexis Inc. said that its board approved a plan to dissolve the company and liquidate its assets. After evaluating the company's strategic options, the Board of Directors reached the conclusion that it is in the best interest of the shareholders to dissolve and liquidate the company.
Crown Bioscience Inc. and Horizon Discovery Ltd. will highlight the availability of X-MAN cell lines for in vitro and in vivo drug discovery model validation. Human disease models are crucial for generating patient-relevant targets and facilitating the development of novel oncology targets.
Medivir AB, announced plans for a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen’s protease inhibitor simeprevir and Vertex’s nucleotide analogue hepatitis C virus polymerase inhibitor VX-135.
Poxel SA announced that in a Phase 2 study Imeglimin, a novel compound in development for Type 2 diabetes, showed incremental efficacy as an add-on therapy to sitagliptin, in patients inadequately controlled by sitagliptin monotherapy. Data from the Phase 2 trial assessed the clinical benefit of adding imeglimin to sitagliptin in 150 patients.
Optimer Pharmaceuticals Inc. announced that the first patient has been dosed in its DEFLECT-1, Phase 3b clinical trial of Dificid tablets for the prevention of Clostridium difficile-associated diarrhea (CDAD) in patients undergoing a bone marrow transplantation.
Agilent Technologies Inc. introduced SureSelect Human All-Exon V5 and V5 + UTRs for next-generation sequencing. The all-exon solutions incorporate the latest advances from Agilent Genomics, the originator of target enrichment for human exomes.
Control Company’s traceable memory-card humidity/temperature/dew point is a stand-alone unit with data logging capabilities. Stores readings from once a minute to once every 720 minutes on a removable standard SD memory card—identical to cards in digital cameras.
To protect light sensitive samples, Porvair Sciences offers a selection of black microplates and seals that eliminate sample degradation, even over long storage periods.
Cyclacel Pharmaceuticals Inc. announced the publication of results from a Phase 2 randomized trial of single-agent sapacitabine in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) or AML in first relapse.
Warner Chilcott PLC said its net income more than tripled in the third quarter, as restructuring costs decreased, which counteracted weakening sales of its osteoporosis drug Actonel. In the third quarter of 2011 Warner Chilcott spent $45 million restructuring its Western European operations.
Ariad Pharmaceuticals Inc. said that it took a bigger loss in the third quarter as it continued development of its experimental cancer drug ponatinib. The Food and Drug Administration is reviewing ponatinib for use against treatment-resistant chronic myeloid leukemia.
An experimental malaria vaccine once thought promising is turning out to be a disappointment, with a new study showing it is only about 30% effective at protecting infants from the killer disease. That is a significant drop from a study last year done in slightly older children.